Baiyunshan and huangtuyiyuan increase the research and development of traditional Chinese Medicine

　　 On May 5, the national development and Reform Commission, together with the national health and Family Planning Commission, the Ministry of human resources and social security, issued the opinions on promoting the reform of drug prices It was decided to cancel most of the government pricing of drugs from June 1, 2015, simultaneously improve the drug procurement mechanism, strengthen the role of medical insurance in charge control, strengthen the supervision of medical behaviors and price behaviors, and establish a market-oriented Drug price formation mechanism This good news immediately got a positive response from the enterprise Baiyunshan and huangtraditional Chinese medicine, a well-known pharmaceutical enterprise with many famous and excellent Chinese patent products, including Baiyunshan Banlangen, Baiyunshan compound danshen tablet, Baiyunshan Yanqing, Baiyunshan Xiaoyan Lidan tablet, etc., has recently announced that it will spend another billion yuan to increase the secondary development and upgrading of traditional medicines such as Banlangen and compound Danshen tablet This is another big move after Baiyunshan and huangtraditional Chinese medicine "invested 1 billion yuan to expand gap planting base and GMP production workshop of Baiyunshan Compound Danshen tablets, Baiyunshan Banlangen and other raw materials" in May last year In recent years, Baiyunshan and huangtraditional Chinese medicine take "scientific and technological innovation" as one of the important development strategies of the enterprise, continuously increase the investment in scientific research, and actively promote the secondary development and upgrading of traditional Chinese medicine products Baiyunshan and Huang's increased investment in scientific research and secondary development not only promote the efficacy of Baiyunshan Compound Danshen tablets, Baiyunshan Banlangen, Baiyunshan Kouyanqing granules and other products, but also inject new connotation and vitality into the development of these classic good drugs, and win the recognition of the market and consumers Industry insiders believe that in the future, through the improvement of drug purchase mechanism and the reform of medical insurance payment mode, it is possible to promote the drug market to "expel the bad currency from the good currency", and it is expected to reverse the phenomenon that "the production cost of cheap drugs approaches the selling price" in recent years Take Baiyunshan Xiaoyan Lidan tablet produced by Baiyunshan and Huang as an example Its sales volume in 2012 was nearly 100 million yuan, with a large number of users Baiyun Mountain and Huang traditional Chinese medicine have also established gap planting bases in Qingyuan and Taishan of Guangdong Province They use the most advanced and efficient film coating materials in the world, double frequency ultrasonic enhanced extraction technology and fingerprint technology to control product quality However, due to the cost problem, the product is at a loss Now, after the introduction of the new drug price policy, the heads of Baiyunshan and Huang said they would increase the production of the product to ensure market supply Li Chuyuan, chairman of Guangyao group, said that Guangyao group has more than 2000 drug approvals, but a considerable part of them have not been produced This is because the price of some drugs is inversely linked to the price, resulting in many big brands of low-cost drugs can not be produced Nowadays, there are more well-known brand enterprises like Baiyunshan and huangtraditional Chinese medicine, which will increase the production and supply of some classic drugs Enterprises can independently set or adjust the retail price according to the drug production cost and market supply and demand, so as to ensure reasonable profits For this reason, part of the cheap drug market will be restored, so that people have more autonomy and choice in drug use